FamiCord announced that it is acquiring Stemlab, positioning it to control the largest cord blood bank in Portugal. To execute the transaction, Polski Bank Komórek Macierzystych S.A. (better known as the Polish Stem Cell Bank or PBKM), a leading company of the global Famicord Group, is acquiring a controlling interest in Stemlab. It will be acquiring 95.6% of the company stock for a purchase price of $16.5M. [Read more…]
Nohla Therapeutics Receives FDA Fast Track Designation for Dilanubicel for Allogeneic Cord Blood Transplant Patients
SEATTLE, Aug. 06, 2018 — Nohla Therapeutics, a leading developer of universal, off-the-shelf cell therapies for patients with hematologic malignancies and other critical diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to dilanubicel (NLA101) for patients with high-risk hematologic malignancies receiving an allogeneic cord blood transplant. Dilanubicel has already received PRIME designation from the European Medicines Agency, and Orphan Drug Designation from the FDA and European Commission. [Read more…]
CryoHoldco Acquires Criocord, a Peruvian Cord Blood Bank and Cell Therapy Institute
CryoHoldco has announced the acquisition of Criocord, a cord blood bank and cell therapy institute in Perù, for an undisclosed sum. CryoHoldco already owns the cord blood market leaders in Mexico and Colombia and now controls an important asset in Peru. A portfolio company of ACON investments, CryoHoldco is a stem cell bank holding company that is the market leader in Latin America and one of the largest cord blood banks worldwide. [Read more…]
Evolution of the Cord Blood Banking Market – Transplant Medicine to RM to Longevity
Cord blood banking initially emerged as a commercial service in the late 1980’s and early 1990’s, because of potential applications related to Transplant Medicine. While an effective therapeutic approach, this unfortunately produced low utilization rates for stored cord blood units.
As a result, Regenerative Medicine (RM) applications of cord blood emerged over time, expanding approved used for cord blood to approximately 80 total. Exciting regenerative medicine applications for umbilical cord blood include its potential to treat neurological conditions, such as cerebral palsy (CP) and autism. These applications are being researched by one of the luminaries in the field, Dr. Joanne Kurtzberg of the Duke Center for Autism and Brain Development and the Carolinas Cord Blood Bank.
As the cord blood market has expanded to include a wide range of perinatal tissues, including umbilical cord tissue, placental blood and tissue, and amniotic fluid and tissue, the new frontier has become Longevity applications. Perinatal is a term describing the period right before and after birth. [Read more…]
Best Cord Blood Banking Conferences
Cord blood conferences have been expanding in number and frequency over the past decade. Cord blood banking is the long-term storage and preservation of umbilical cord blood collected during the birth of a newborn. It is collected, because it is rich in hematopoietic stem cells (HSCs), a stem cell type that is widely used in transplant medicine and can be used to treat over 80 different conditions. The matrix of the umbilical cord, called Wharton’s Jelly, is also a rich source of mesenchymal stem cells (MSCs), a cell type that is now being explored in more than 800 clinical trials worldwide.
Each year, cord blood industry experts gather at these events to discuss trends, research progress, and clinical and technological advances.
Below, we highlight leading cord blood industry events, many of which BioInformant attends, sponsors, or helps to organize. [Read more…]
- « Previous Page
- 1
- …
- 10
- 11
- 12
- 13
- 14
- …
- 30
- Next Page »